NDAORALCAPSULE
Approved
Jan 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDIONE (trimethadione) is an oral oxazolidinedione anticonvulsant approved in 1946 for seizure management. It is a small-molecule drug administered as capsules for patients with specific seizure disorders. The exact mechanism of action and current indications are not fully detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, suggesting small brand team and focus on defensive maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIDIONE offers limited career growth potential given its LOE-approaching status and minimal job openings. Roles focus on maintaining market position and ensuring compliance rather than innovation or expansion.
Brand ManagerSales Representative
Worked on TRIDIONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.